NASDAQ:INVA

Innoviva (INVA) Stock Price, News & Analysis

$14.97
-0.19 (-1.25%)
(As of 10:44 AM ET)
Today's Range
$14.95
$15.09
50-Day Range
$14.40
$16.00
52-Week Range
$11.37
$16.86
Volume
43,546 shs
Average Volume
671,270 shs
Market Capitalization
$946.55 million
P/E Ratio
6.87
Dividend Yield
N/A
Price Target
N/A

Innoviva MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Bearish
18.15% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.33
Upright™ Environmental Score
News Sentiment
1.03mentions of Innoviva in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.49 out of 5 stars

Medical Sector

666th out of 907 stocks

Pharmaceutical Preparations Industry

302nd out of 422 stocks

INVA stock logo

About Innoviva Stock (NASDAQ:INVA)

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

INVA Stock Price History

INVA Stock News Headlines

World’s biggest multibillionaire investor is buying THIS by the ton [picture]
Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.
World’s biggest multibillionaire investor is buying THIS by the ton [picture]
Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.
Innoviva Inc INVA
Cosmo Pharmaceuticals NV COPN
3 Lucrative Biotech Stock Buys for Success
Innoviva: A Lot Of Moving Parts
See More Headlines
Receive INVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Innoviva and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/29/2024
Today
4/25/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:INVA
Previous Symbol
NASDAQ:THRX
CUSIP
88338T10
Employees
112
Year Founded
1996

Profitability

Net Income
$179.72 million
Pretax Margin
62.52%

Debt

Sales & Book Value

Annual Sales
$310.46 million
Cash Flow
$3.49 per share
Book Value
$10.66 per share

Miscellaneous

Free Float
62,342,000
Market Cap
$958.57 million
Optionable
Optionable
Beta
0.57

Social Links

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

INVA Stock Analysis - Frequently Asked Questions

How have INVA shares performed in 2024?

Innoviva's stock was trading at $16.04 on January 1st, 2024. Since then, INVA stock has decreased by 5.5% and is now trading at $15.16.
View the best growth stocks for 2024 here
.

Are investors shorting Innoviva?

Innoviva saw a decline in short interest in the month of March. As of March 31st, there was short interest totaling 11,330,000 shares, a decline of 13.0% from the March 15th total of 13,020,000 shares. Based on an average daily volume of 681,300 shares, the days-to-cover ratio is presently 16.6 days. Currently, 18.2% of the company's shares are sold short.
View Innoviva's Short Interest
.

When is Innoviva's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our INVA earnings forecast
.

How were Innoviva's earnings last quarter?

Innoviva, Inc. (NASDAQ:INVA) announced its earnings results on Thursday, February, 29th. The biotechnology company reported $0.76 earnings per share (EPS) for the quarter. The biotechnology company earned $85.84 million during the quarter. Innoviva had a net margin of 57.89% and a trailing twelve-month return on equity of 30.37%.

What other stocks do shareholders of Innoviva own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Innoviva investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Exelixis (EXEL), Micron Technology (MU), Advanced Micro Devices (AMD), Pfizer (PFE), Vertex Pharmaceuticals (VRTX), NVIDIA (NVDA), OPKO Health (OPK) and Sorrento Therapeutics (SRNE).

Who are Innoviva's major shareholders?

Innoviva's stock is owned by many different retail and institutional investors. Top institutional shareholders include Denali Advisors LLC (0.52%), Los Angeles Capital Management LLC (0.22%), Allspring Global Investments Holdings LLC (0.18%) and GAMMA Investing LLC (0.00%). Insiders that own company stock include Alexander J Denner, George Bickerstaff, Innoviva, Inc, Marianne Zhen, Pavel Raifeld and Plc Glaxosmithkline.
View institutional ownership trends
.

How do I buy shares of Innoviva?

Shares of INVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:INVA) was last updated on 4/25/2024 by MarketBeat.com Staff

From Our Partners